Clearside Biomedical, Inc. (CLSDQ)
OTCMKTS · Delayed Price · Currency is USD
0.2490
0.00 (0.00%)
Inactive · Last trade price on Jul 13, 2026
Clearside Biomedical Revenue
Clearside Biomedical had revenue of $201.00K in the quarter ending September 30, 2025, a decrease of -80.64%. This brings the company's revenue in the last twelve months to $3.33M, down -56.78% year-over-year. In the year 2024, Clearside Biomedical had annual revenue of $1.66M, down -79.77%.
Revenue (ttm)
3.33M
Revenue Growth
-56.78%
P/S Ratio
5.51
Revenue / Employee
104.03K
Employees
32
Market Cap
18.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.66M | -6.56M | -79.77% |
| Dec 31, 2023 | 8.23M | 6.90M | 519.89% |
| Dec 31, 2022 | 1.33M | -28.25M | -95.51% |
| Dec 31, 2021 | 29.58M | 21.68M | 274.65% |
| Dec 31, 2020 | 7.89M | 5.72M | 263.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionClearside Biomedical News
- 8 days ago - Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor - Business Wire
- 8 months ago - Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - GlobeNewsWire
- 8 months ago - Clearside Biomedical Quarterly report: Q3 2025 - Filings
- 11 months ago - Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress - GlobeNewsWire
- 1 year ago - Clearside Biomedical Quarterly report: Q2 2025 - Filings
- 1 year ago - Clearside Biomedical Proxy statement: Proxy Filing - Filings
- 1 year ago - Clearside Biomedical Proxy statement: Proxy Filing - Filings
- 1 year ago - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - GlobeNewsWire